Comparison of neoadjuvant chemotherapy effect between regimen TAC and TEC in patients with breast cancer

Meng-fang ZANG,Xiang-cheng ZHI,Min ZHANG,Feng GU

DOI: https://doi.org/10.3969/j.issn.1002-266X.2011.06.011

2011-01-01

Abstract:Objective To compare the clinical efficacy of TAC and TEC as the neoadjuvant chemotherapy regimens in the treatment of breast cancer.Methods 139 cases of breast cancer patients were collected and randomly divided into TAC group(71 cases) and TEC group(68 cases).The two groups were received TAC(docetaxel+ pirarubicin+ cyclophosphamide) or TEC(docetaxel+ epirubicin+ cyclophosphamide) regimen as neoadjuvant chemotherapy respectively.Clinical responses and side effects were assessed after neoadjuvant chemotherapy 4~6 cycles.Results The overall response rate(RR),pathologic complete remission(pCR),clinical complete remission(cCR),clinical partial remission(cPR),stable disease(SD)of group TAC respectively were 88.7%、11.3%、28.2%、60.6% and 11.3%.TEC group respectively were 86.8%、10.3%、26.5%、60.3% and 13.2%.There was no difference between the two groups(P>0.05).In side effects,including leukopenia,thrombocytopenia,constipation,cardiotoxity,abnormality and hepatorenal dysfunction,there was also no significant difference(P>0.05).Only the gastroenteric reaction including nausea and vomiting,the TAC group(46.5%) lower to TEC group(66.2%)(P<0.05).All patients received operation after neoadjuvant chemotherapy.Conclusions TAC and TEC regimen treated breast cancer are both effective and have little side effects.Pirarubicin as well as epirubicin can be used conventional in neoadjuvant chemotherapy of breast cancer.